摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-chloroquinoline-2,4-dicarboxylic acid | 330646-88-3

中文名称
——
中文别名
——
英文名称
8-chloroquinoline-2,4-dicarboxylic acid
英文别名
——
8-chloroquinoline-2,4-dicarboxylic acid化学式
CAS
330646-88-3
化学式
C11H6ClNO4
mdl
——
分子量
251.626
InChiKey
CYBPXAPZONTLOR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    87.5
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 储存条件:
    室温

反应信息

  • 作为反应物:
    描述:
    8-chloroquinoline-2,4-dicarboxylic acid氯化亚砜 作用下, 反应 16.0h, 生成
    参考文献:
    名称:
    第一种高选择性GLUT1抑制剂BAY-876的鉴定和优化。
    摘要:
    尽管众所周知的事实是,即使在正常的氧气供应条件下,促进性葡萄糖转运蛋白GLUT1仍是保证许多肿瘤实体葡萄糖消耗增加的关键因素之一(被称为Warburg效应),但仅进行了很少的努力寻找一种GLUT1选择性小分子抑制剂。由于GLUT1家族的其他转运蛋白都参与关键过程,因此此类抑制剂不应解决这些转运蛋白。针对约300万种化合物的库进行了高通量筛选,以发现具有这种具有挑战性的效能和选择性的小分子。N-(1H-吡唑-4-基)喹啉-4-羧酰胺被确定为进一步优化化合物的理想起点。经过广泛的构效关系探索后,获得了对GLUT2,GLUT3和GLUT4的选择性因子> 100的个位数纳摩尔抑制剂。最有前途的化合物BAY-876 [N4- [1-(4-氰基苄基)-5-甲基-3-(三氟甲基)-1H-吡唑-4-基] -7-氟喹啉-2,4-二甲酰胺]在体外具有良好的代谢稳定性,在体内具有较高的口服生物利用度。
    DOI:
    10.1002/cmdc.201600276
  • 作为产物:
    描述:
    7-氯靛红sodium pyruvate 在 sodium hydroxide 作用下, 以 为溶剂, 生成 8-chloroquinoline-2,4-dicarboxylic acid
    参考文献:
    名称:
    Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold
    摘要:
    Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold. We have explored the effects of substituting the quinoline ring and varying the position of its sp(2) hybridized nitrogen atom. The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indices (>10(3)) with respect to both the DPPs and PREP. Preliminary experiments on a representative inhibitor demonstrate that plasma stability, kinetic solubility, and log D of this class of compounds can be expected to be satisfactory.
    DOI:
    10.1021/ml300410d
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL FAP INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE FAP
    申请人:UNIV ANTWERPEN
    公开号:WO2013107820A1
    公开(公告)日:2013-07-25
    The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    本发明涉及对FAP(成纤维细胞活化蛋白)具有高选择性和特异性的新型抑制剂。所述抑制剂可用作人类和/或兽药,特别是用于治疗和/或预防FAP相关疾病,如但不限于增殖性疾病。
  • NOVEL FAP INHIBITORS
    申请人:UNIVERSITEIT ANTWERPEN
    公开号:US20140357650A1
    公开(公告)日:2014-12-04
    The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    本发明涉及具有高选择性和特异性的新型抑制剂,用于FAP(成纤维细胞激活蛋白)。所述抑制剂可用作人类和/或兽医药物,特别用于治疗和/或预防与FAP相关的疾病,如但不限于增殖性疾病。
  • [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
    申请人:BAYER PHARMA AG
    公开号:WO2015091428A1
    公开(公告)日:2015-06-25
    The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及选择性抑制葡萄糖转运蛋白1(GLUT1)的化合物,涉及制备该类化合物的方法,包括含有该类化合物的药物组合物和药物组合物,以及利用该类化合物制造用于治疗或预防疾病的药物组合物的用途,还涉及在制备该类化合物中有用的中间体化合物。
  • GLUCOSE TRANSPORT INHIBITORS
    申请人:Bayer Pharma Aktiengesellschaft
    公开号:EP3083598A1
    公开(公告)日:2016-10-26
  • US9346814B2
    申请人:——
    公开号:US9346814B2
    公开(公告)日:2016-05-24
查看更多